Core Viewpoint - The Chinese medical device industry has maintained a high level of business development (BD) activity over the past three months, with various forms of collaboration emerging, including mergers and acquisitions, technology partnerships, channel authorizations, and industry chain collaborations, indicating an acceleration in capital integration and industrial synergy within the sector [2][22]. Overview of BD Events - Approximately 30 BD events in the medical device sector were recorded from December 2025 to March 2026, with significant activity in cardiovascular and interventional devices, as well as IVD industry chain collaborations [5][6]. Event Type Structure - The BD activities are characterized by a clear structure, with strategic and technical collaborations being the most prevalent, involving joint R&D, supply chain collaboration, and channel partnerships. Equity acquisitions and asset mergers, while fewer in number, have a more substantial impact on the industry landscape [6][19]. Notable Transactions - Key transactions include: - Heartlink Medical's acquisition of Micro-Invasive Cardiac Management for $680 million, expanding its product portfolio to a comprehensive cardiovascular platform [10][12]. - Midea Medical's acquisition of Carestream International's imaging assets, enhancing its global market capabilities [11][12]. - Aibo Medical's acquisition of 68.31% of Demai Medical for 683 million yuan, entering the sports medicine device sector [12][13]. - Guichuang Tongqiao's investment in German company Optimed, reflecting the trend of Chinese interventional device companies integrating European technology and market resources [13][18]. - Baiyang Medical's joint venture with ZAP Surgical to establish a production base for the ZAP-X robotic system, showcasing collaboration in high-end medical equipment [14][18]. Trends in BD Activities - Overseas acquisitions have become a crucial path for Chinese companies to acquire technology, with many transactions involving foreign assets [15][18]. - There is a noticeable increase in collaborative efforts focused on supply chain and industry chain synergy, indicating a shift from single product competition to ecosystem collaboration [19][22]. - Channel partnerships remain a significant method for multinational companies to enter the Chinese market, reflecting the expanding scale of the domestic medical device market [20][22]. - Collaborations centered around technology platforms are on the rise, indicating a transition towards systematic medical technology platform development [21][22].